Clariane & ALCEDIAG present real-world data confirming the high acceptability of the myEDIT-B test in routine care at the European Congress of Neuropsychopharmacology (ECNP)
The world’s first blood test designed to help clinicians distinguish unipolar depression from bipolar disorder, myEDIT-B has demonstrated a high level of acceptability and clinical utility to psychiatrists and their patients in a European real-world study.
Based on RNA editing and artificial intelligence, the myEDIT-B test reflects an emerging focus on precision psychiatry, providing a biological tool that complements clinical diagnosis.
Conclusive results in the field
As part of Clariane’s approach to evaluating health innovations, an acceptability study accompanied the rollout of the myEDIT-B test, which was prescribed as part of routine care for 63 adult patients under monitoring for a moderate or severe major depressive episode. The study was carried out in real care settings, in Clariane’s mental health clinic networks in France (Inicea) and Spain (Ita Salud Mental), as well as at Hospital Clínic de Barcelona, with the assistance of SYNLAB laboratories for biological analyses.
The psychiatrists who took part in the study highlight the test’s concrete impact on their practice:
- 83% report that myEDIT-B helped them guide or redirect patients’ treatment;
- 100% believe that it has strengthened the therapeutic alliance with their patients;
- 67% believe that it has helped reduce the time to diagnosis;
- 92% indicate that it made communicating the diagnosis easier;
- 92% say it confirmed or disproved the initial diagnosis.
These data reaffirm the value of integrating diagnostic tests into psychiatric care pathways to incorporate precision medicine.
A major public health issue
Bipolar disorder remains underdiagnosed or diagnosed late, with an average of eight years between the first symptoms and the implementation of appropriate treatment (McIntyre et al., 2020). This delay leads to significant clinical and social consequences, including worsened symptoms, relapses, excess mortality and impaired quality of life.
In this context, a tool like myEDIT-B represents a major step forward. Available on prescription, it is intended for adult patients receiving treatment for a moderate or severe major depressive episode to help psychiatrists manage their treatment more effectively.
Our partnership with Alcediag is fully in line with Clariane’s approach to innovation and research as part of its status as a purpose-driven company. We are pleased with the results of the real-world experiment conducted with our medical teams: our trial of myEDIT-B® shows that diagnostic tools provide support for clinicians and benefit patients by enabling them to access the most appropriate treatment for their condition more quickly. The project also illustrates our desire to improve the care we provide to our patients and to help drive forward innovations for comprehensive and personalised care.”
After more than ten years of continuous efforts to improve diagnostic pathways and bring concrete benefits to patients and psychiatrists, we’re proud to be working in partnership with Clariane, an organisation that shares our values of innovation and our commitment to the quality of care offered to patients.
L’étude, intitulée « Résultats préliminaires d’une étude en vie réelle sur l’acceptabilité d’un premier test sanguin basé sur l’édition de l’ARN : un outil au service de la psychiatrie de précision », a été présentée lors du congrès de l’ECNP 2025 à Amsterdam. Le poster présenté a été sélectionné par le comité scientifique du congrès européen de psychiatrie de cet événement et a obtenu un prix poster à la journée scientifique Clariane à l’Université Paris Cité.
